DAPT (gamma-secretase inhibitor)

DAPT is a drug that blocks gamma-secretase, an enzyme critical in producing amyloid-beta peptides involved in Alzheimer’s disease. Amyloid-beta accumulates to form plaques in the brain, which are linked to memory loss and cognitive decline. By inhibiting gamma-secretase, DAPT aims to reduce amyloid-beta production, potentially slowing or preventing plaque formation. While promising, gamma-secretase inhibitors like DAPT are under investigation to balance reducing amyloid without disrupting other essential cellular processes. Researchers hope this approach could offer a targeted way to treat or prevent Alzheimer’s disease, but more studies are needed to confirm safety and effectiveness.